logo
Plus   Neg
Share
Email

Seattle Genetics, Astellas, Merck To Evaluate Enfortumab Vedotin Plus KEYTRUDA

Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. have entered a clinical collaboration agreement with Merck to evaluate the combination of Seattle Genetics' and Astellas' antibody-drug conjugate enfortumab vedotin and Merck's anti-PD-1 therapy, KEYTRUDA, in patients with previously untreated metastatic urothelial cancer. The companies will conduct a global, registrational phase 3 clinical trial to be led by Seattle Genetics. The companies currently plan to initiate the trial in the first half of 2020.

Enfortumab vedotin is currently under review by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The PDUFA action date is March 15, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chinese media company SINA Corp. (SINA) announced Monday that it has agreed yo a going private deal with New Wave Holdings Ltd., pursuant to which New Wave will acquire all of SINA's outstanding ordinary shares, not currently owned by it, in an all-cash transaction implying an equity value of the Company... Amazon Prime Day, the e-commerce giant's biggest shopping event of the year, is taking place on October 13 and 14, just after Canadian Thanksgiving. Amazon Prime members could get early access to Prime Day offers and deals every day, starting from today, up to the event in October. The two-day shopping event, which is usually held in the U.S. in mid-July, comes much delayed due to the coronavirus. Secaucus, New Jersey-based The Vitamin Shoppe is recalling Vthrive Bioactive Multivitamins citing risk of poisoning as it failed to meet child resistant packaging requirements, according to the U.S. Consumer Product Safety Commission. The recall involves about 8,200 units of Vthrive Bioactive Women's One-Daily Multi vitamins manufactured in United States.
Follow RTT